Refanezumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | myelin-associated glycoprotein |
| Identifiers | |
| CAS Number | 1233953-61-1 |
| ATC code | none |
| Chemical data | |
| Formula | C6608H10156N1732O2064S44 |
| Molecular mass | 148.3 kg/mol |
Refanezumab is a monoclonal antibody designed for the recovery of motor function after stroke.[1]
This drug was developed by GlaxoSmithKline.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Refanezumab, American Medical Association.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibody stubs
- Monoclonal antibodies
